The Lund-based medical device company Lumito AB has initiated a process to list the Company's shares and warrants on Nasdaq First North Growth Market.
As part of this process, a conditional application for delisting from NGM Nordic SME has been submitted to NGM. The application is conditional on Nasdaq’s approval of Lumito for listing on First North Growth Market.
The last day of trading on NGM Nordic SME and the first day of trading on Nasdaq First North Growth Market will be announced when the Company's applications have been approved by the respective trading venues.
No action needs to be taken by holders of shares and warrants in Lumito in conjunction with the planned change of listing.
G&W Fondkommission, which also has been the Company’s Mentor at NGM Nordic SME, will be the Certififed Adviser for the planned listing on Nasdaq First North Growth Market.
For more information, please contact:
Urban Widén, acting CEO of Lumito AB (publ)
Telephone: +4676-778 59 05, Email: uw@lumito.se
See also www.lumito.se.
Lumito specializes in imaging technology within medical research and development. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito´s IPR covers high-quality imaging of tissue, for instance in tumours, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology. www.lumito.se
Lumito's share is traded under the ticker LUMITO on the Nordic Growth Market, NGM SME, where the Company's mentor is G&W Fondkommission, telephone: +468-503 000 50.
